Goldline Pharmaceutical Ltd - 544759 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Goldline Pharmaceutical's Promoter and Whole Time Director, Swapan Khandelwal, acquired 60,000 equity shares via open market purchase. This transaction increased his total shareholding by 0.62% to 29.27%.
Jun 24 2026 13:20:06
Goldline Pharmaceutical Ltd - 544759 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Goldline Pharmaceutical's Promoter and Whole Time Director, Mr. Swapan Khandelwal, acquired 60,000 equity shares, raising his stake by 0.62%. This open market purchase brings his total holding to 29.27%.
Jun 24 2026 13:19:00
Goldline Pharmaceutical Ltd - 544759 - Disclosure Under Regulation 29 (2) Of Securities And Exchange Board Of India (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
Goldline Pharmaceutical's Promoter and Whole Time Director, Mr. Swapan Khandelwal, acquired 60,000 shares (0.62% stake) through open market purchase on June 22, 2026. This increases his total holding to 29.27%.
Jun 23 2026 20:37:38
Goldline Pharmaceutical Ltd - 544759 - Board Meeting Outcome for Outcome Of Board Meeting Held Today, I.E., 09Th June, 2026
Goldline Pharmaceutical's board approved audited FY26 financial results, with revenue growing 11.20% YoY to ₹31.20 crores and net profit increasing 45.26% YoY to ₹4.12 crores. The board also appointed M/s. Kunal Dutt & Associates as the internal auditor from FY27.
Jun 09 2026 19:00:27
Goldline Pharmaceutical Ltd - 544759 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 To Be Held On Tuesday, June 09, 2026.
Goldline Pharmaceutical will hold a board meeting on June 9, 2026. The meeting agenda includes the consideration and approval of standalone audited financial results for the half-year and full year ended March 31, 2026.
Jun 02 2026 16:01:14
Read More